Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

Clin Cancer Res. 2023 Oct 2;29(19):3832-3834. doi: 10.1158/1078-0432.CCR-23-1736.

Abstract

The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Estradiol / pharmacology
  • Estrogens
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Receptors, Estrogen

Substances

  • Receptors, Estrogen
  • Estradiol
  • Immune Checkpoint Inhibitors
  • Estrogens